Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy.
Launched by INSTITUTO VALENCIANO DE INFERTILIDAD, IVI VALENCIA · Jun 9, 2017
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion criteria:
- • Written informed consent
- • Patients undergoing their first or second IVF-ET cycle
- • Age 18-45 years
- • Use of Ovitrelle for final follicular maturation and luteinization
- • Fresh or Frozen day-5 blastocysts transrer (Autologus or Egg donation)
- Exclusion criteria:
- • Gestational surrogacy (patient's eggs used for pregnancy in a surrogate mother)
- • Canceled IVF cycles
- • GnRH agonist triggering cycles in the case of fresh ET.
About Instituto Valenciano De Infertilidad, Ivi Valencia
Instituto Valenciano de Infertilidad (IVI Valencia) is a leading fertility clinic and research institution dedicated to advancing reproductive health and assisted reproductive technologies. With a commitment to providing personalized care and innovative treatment options, IVI Valencia conducts clinical trials aimed at enhancing the understanding and effectiveness of infertility therapies. The institute combines state-of-the-art facilities with a team of experienced specialists, ensuring high standards of patient safety and ethical research practices. IVI Valencia plays a pivotal role in fostering scientific advancements in the field of reproductive medicine, ultimately striving to improve outcomes for individuals and couples facing fertility challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Patients applied
Trial Officials
Ernesto Bosch, MDPhD
Principal Investigator
IVIRMA VALENCIA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials